Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate. The company was founded in 2006 and is headquartered in Toronto, Canada.
| 0.008 | |
| 0.008 | |
| - | |
| 0.008 | |
| 0.008 | |
| 0.0021-0.0595 | |
| 1 096 K | |
| 137 M | |
| 0 | |
| -0.0003 | |
| -3.671 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
The Digital Issue of the Summer 2020 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / August 11, 2020 ...
The Digital Issue of the Summer 2020 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / August 11, 2020 ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
